Researchers emphasized that the benefit persisted well beyond the treatment period, reinforcing the clinical rationale for time-limited therapy in selected patients
Findings show growing optimism across the pharma sector as dealmaking accelerates, innovation strengthens, and companies adapt to tariffs, pricing reforms, and looming patent expirations
Despite the disruption, the company stressed that “our core business operations are not impacted and remain up and running.
The filing is backed by Phase III data from the lidERA Breast Cancer study
The filing is backed by results from the pivotal SERENA-6 Phase III trial
Sarin will focus on advancing scalable AI-driven platforms and strengthening the company’s global data science capabilities across healthcare and enterprise technology domains
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
Highlights strong Vibegron results in older men & real-world prostate cancer insights
AI and analytics leader brings extensive expertise in machine learning, GenAI, and life sciences decision intelligence to Lilly’s data science operations
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
